1. Home
  2. CUZ vs TGTX Comparison

CUZ vs TGTX Comparison

Compare CUZ & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUZ
  • TGTX
  • Stock Information
  • Founded
  • CUZ 1958
  • TGTX 1993
  • Country
  • CUZ United States
  • TGTX United States
  • Employees
  • CUZ N/A
  • TGTX N/A
  • Industry
  • CUZ Real Estate Investment Trusts
  • TGTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • CUZ Real Estate
  • TGTX Health Care
  • Exchange
  • CUZ Nasdaq
  • TGTX Nasdaq
  • Market Cap
  • CUZ 4.8B
  • TGTX 5.1B
  • IPO Year
  • CUZ N/A
  • TGTX 1995
  • Fundamental
  • Price
  • CUZ $28.77
  • TGTX $36.71
  • Analyst Decision
  • CUZ Buy
  • TGTX Strong Buy
  • Analyst Count
  • CUZ 10
  • TGTX 5
  • Target Price
  • CUZ $32.80
  • TGTX $45.00
  • AVG Volume (30 Days)
  • CUZ 1.5M
  • TGTX 2.0M
  • Earning Date
  • CUZ 10-30-2025
  • TGTX 11-03-2025
  • Dividend Yield
  • CUZ 4.45%
  • TGTX N/A
  • EPS Growth
  • CUZ N/A
  • TGTX N/A
  • EPS
  • CUZ 0.37
  • TGTX 0.36
  • Revenue
  • CUZ $917,942,000.00
  • TGTX $454,069,000.00
  • Revenue This Year
  • CUZ $14.21
  • TGTX $82.22
  • Revenue Next Year
  • CUZ $2.84
  • TGTX $47.76
  • P/E Ratio
  • CUZ $77.47
  • TGTX $101.75
  • Revenue Growth
  • CUZ 11.98
  • TGTX 30.96
  • 52 Week Low
  • CUZ $24.07
  • TGTX $21.16
  • 52 Week High
  • CUZ $32.55
  • TGTX $46.48
  • Technical
  • Relative Strength Index (RSI)
  • CUZ 50.60
  • TGTX 69.29
  • Support Level
  • CUZ $28.54
  • TGTX $34.52
  • Resistance Level
  • CUZ $29.30
  • TGTX $37.55
  • Average True Range (ATR)
  • CUZ 0.48
  • TGTX 1.22
  • MACD
  • CUZ -0.04
  • TGTX 0.29
  • Stochastic Oscillator
  • CUZ 51.39
  • TGTX 86.50

About CUZ Cousins Properties Incorporated

Cousins Properties Inc is a real estate investment trust principally involved in the ownership, management, and development of properties in the Southern United States. Cousins Properties' real estate portfolio mainly comprises offices and mixed-use developments that encompass both apartment and retail space. Offices make up the vast majority of the portfolio in terms of total square footage. The segments operates in following geographical areas: Atlanta, Austin, Charlotte, Dallas, Phoenix, Tampa, and other markets. The company derives nearly all of its revenue in the form of rental income from its properties, the majority of which comes from its office locations. A diverse set of tenants in the cities of Houston and Atlanta represent the company's key markets.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Share on Social Networks: